These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26119932)

  • 1. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
    Flashner-Abramson E; Klein S; Mullin G; Shoshan E; Song R; Shir A; Langut Y; Bar-Eli M; Reuveni H; Levitzki A
    Oncogene; 2016 May; 35(20):2675-80. PubMed ID: 26119932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
    Yu S; Wang Y; Lv K; Hou J; Li W; Wang X; Guo H; Wang W
    Technol Cancer Res Treat; 2021; 20():15330338211027916. PubMed ID: 34238066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
    Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
    Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
    de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
    Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.
    Su SP; Flashner-Abramson E; Klein S; Gal M; Lee RS; Wu J; Levitzki A; Daly RJ
    Mol Cancer Ther; 2018 May; 17(5):931-942. PubMed ID: 29440449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor.
    Rampias T; Favicchio R; Stebbing J; Giamas G
    Oncogene; 2016 May; 35(20):2562-4. PubMed ID: 26477311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
    Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
    Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for targeting the STAT3 pathway as a novel therapy for melanoma.
    Lesinski GB
    Future Oncol; 2013 Jul; 9(7):925-7. PubMed ID: 23837753
    [No Abstract]   [Full Text] [Related]  

  • 9. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
    Sanchez-Lopez E; Flashner-Abramson E; Shalapour S; Zhong Z; Taniguchi K; Levitzki A; Karin M
    Oncogene; 2016 May; 35(20):2634-44. PubMed ID: 26364612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iciartin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling.
    Wu J; Du J; Fu X; Liu B; Cao H; Li T; Su T; Xu J; Tse AK; Yu ZL
    Oncotarget; 2016 Aug; 7(32):51251-51269. PubMed ID: 27323414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
    Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting IGF1R pathway in cancer with microRNAs: How close are we?
    Kumar AS; Rayala SK; Venkatraman G
    RNA Biol; 2018 Mar; 15(3):320-326. PubMed ID: 28613101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
    Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
    J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.
    Cao HH; Chu JH; Kwan HY; Su T; Yu H; Cheng CY; Fu XQ; Guo H; Li T; Tse AK; Chou GX; Mo HB; Yu ZL
    Sci Rep; 2016 Feb; 6():21731. PubMed ID: 26911838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
    Kim KB
    Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway.
    Kamran MZ; Gude RP
    Biomed Pharmacother; 2013 Jun; 67(5):399-405. PubMed ID: 23639230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling.
    Cao HH; Tse AK; Kwan HY; Yu H; Cheng CY; Su T; Fong WF; Yu ZL
    Biochem Pharmacol; 2014 Feb; 87(3):424-34. PubMed ID: 24275163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.